Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-245 in Relapsed/Refractory Neuroblastoma
NCT05782959Phase 1Unknown
- Sponsor
- BIOCAD
- Start
- Nov 2021
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of donitabart in neuroblastoma (4 cohorts), sponsored by BIOCAD. Primary endpoints: Proportion of subjects with adverse reactions at 52 weeks, Proportion of subjects with serious adverse reactions at 52 weeks and 2 more. Status: unknown.
02
Drugs
donitabart
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT05782959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05782959.